Drugs Made In America Acquisition II Corp.

Although the filing does not update the redemption calendar, trust mechanics, or de-SPAC schedule, it materially affects near-term liquidity and listing survival. The mandatory $400,000 disbursement by March 30, 2026 establishes a concrete cash-inflow checkpoint. The 35% conversion discount and sole-discretion conversion rights favor the lender upon a future combination, potentially diluting existing shareholders at the time of the event. Tracking whether the $1,250,000 remainder closes and how the escrow release mechanism operates will indicate whether management is preserving runway for active target evaluation or merely covering administrative overhead ahead of potential deadlines.

The Sponsor's diversion of working capital for non-company purposes and subsequent failure to repay directly threatens the liquidity pool backing the trust account, posing a material risk to shareholder redemption values and potentially complicating the remaining search timeline. The abrupt leadership change during the SEARCHING phase introduces governance turbulence and execution uncertainty. While the filing does not adjust official redemption deadlines or recalculate per-share trust value, the unresolved status of the unrecovered funds highlights sponsor conduct that could delay or derail a future business combination. The appointment of Roger Bendelac—a 69-year-old consultant with over 30 years of investment banking and advisory experience—signals an attempted operational reset, though his specific compensation arrangements remain pending Board approval.

Sponsor-initiated working capital impropriety introduces governance and proxy-voting risk, signaling potential internal control deficiencies prior to a merger. However, because the board independently verified the diversion was confined to working capital, the full $507,841,957 trust pool remains available for shareholder redemptions, leaving the redemption floor unchanged from the filing's perspective. Reduced working capital may force reliance on external funding or trigger extension negotiations if operating expenses outpace remaining liquidity before a deal closes. The document provides no information on target prospects, customer relationships, revenue streams, market positioning, or technological assets beyond the fund irregularity and its verification.

This filing establishes the baseline trust value ($10.00 per share), the 24-month deadline (September 2027), and the sponsor's reduced ownership. It confirms no deal target has been selected and that the company is searching for a target in the pharmaceutical industry. The going concern disclosure and material weakness in internal controls are notable risk factors. The over-allotment option remains available, which could affect share count. The filing also details related party transactions, including the administrative services agreement and founder share lock-up provisions.

The filing transitions financial oversight to an outsourced specialist during the SPAC's 'SEARCHING' phase, prior to any business combination. Under the Consulting Agreement, the Company pays Titan Advisory Services LLC $3,500 per month, or $42,000 per year. Furthermore, Chief Executive Officer Lynn Stockwell shall transfer 100,000 shares of the Company’s ordinary shares to Mr. Elmasri upon engagement. The new CFO’s profile lists him as a CPA with 20 years of experience in financial and management consulting, beginning at PricewaterhouseCoopers and currently serving as Managing Partner at Titan Advisory Services LLC. Regarding SPAC mechanics, this personnel shift carries no implications for the redemption calendar, triggers no extension votes, leaves the trust value unchanged, and reveals no new deal progress, customer claims, revenue metrics, or litigation. Sponsor conduct remains unremarked upon beyond the standard equity compensation and indemnity expectations outlined for officers.

This filing finalizes the SPAC's funding mechanics and definitive calendar for public shareholders, confirming that $500,000,000 is held in the trust account to back redemption obligations. Management stated the company intends to focus on the pharmaceutical industry but explicitly disclosed that no target has been selected and no substantive discussions have been initiated. Underwriters agreed to waive their right to the $17,500,000 deferred underwriting commissions if a business combination is not completed within the Combination Period, protecting trust value for redeeming investors. Independent auditor MaloneBailey, LLP raised a going concern matter, noting the company has incurred significant costs without generating operating revenues and faces mandatory liquidation if a deal is not consummated, which fundamentally alters the risk assessment for holders of the ordinary shares and rights listed on Nasdaq.

This filing sets the baseline trust value at $10.00 per share and starts the 24-month deadline (to September 26, 2027) for a business combination. It details sponsor lock-up provisions (founder shares and private units subject to 6-month or $12.50 price-based lock-ups), redemption mechanics (public shareholders can redeem upon a business combination or liquidation if no deal, and amendments affecting redemption rights trigger additional redemption opportunities), and the sponsor’s indemnification of the trust account against certain claims. For investors monitoring redemption deadlines and trust value, the key numbers are established: $10.00 per share in trust, $17.5 million deferred underwriting commission, and up to $100,000 from interest for dissolution expenses. The company has not identified a target but intends to focus on pharmaceutical supply chain onshoring.

This filing establishes all of the structural terms and deadlines that govern the SPAC: the exact trust value ($500M / 50M shares = $10.00 per share), the 24-month deadline, the no-redemption-rights for rights, the 15% cap on redemptions if a shareholder vote is used, and the significant dilution from founder shares purchased at $0.0024. It also flags related-party conflicts: Lynn Stockwell runs both DMII and DMAA (a sister SPAC), and DMII must present targets to DMAA first. The Chapter 11 filing of Bright Green Corporation (where Lynne Stockwell is CEO) and ongoing litigation against Lynn and John Stockwell are disclosed. These conflict and bankruptcy disclosures are material for assessing sponsor conduct and deal risk.

The exhibit contains no substantive operational disclosures. No claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel are attributed to management, board members, or sponsors. No numerical performance metrics or timeline updates appear beyond the form identifier and SEC reference number. The explicit absence of reported transactions confirms no covert insider positioning during the SEARCHING phase, though it delivers no forward-looking catalysts, revised distribution thresholds, or governance signals for public shareholders.

Accelerating the S-1 effective date advances the capital raise and deSPAC execution timeline, which directly precedes final pricing, underwriter allocation, and potential business combination announcements that would activate shareholder redemption windows. As reported by David Batalion, Managing Director, Investment Banking at Cantor Fitzgerald & Co., preliminary prospectus distribution to participating dealers is underway. The filing contains no additional substance regarding customer bases, revenue projections, market sizing, strategic pivots, technology developments, partnership agreements, ongoing litigation, or personnel changes.

Accelerating the S-1 declaration establishes the mechanical trigger for when public shares may legally trade and become subject to SPAC redemption rights, directly compressing the timeline for investor capital deployment decisions during the SEARCHING phase. By stipulating that Staff approval does not foreclose future Commission action nor relieve the Company of full disclosure responsibility, the filing frames deal progression strictly as an internal execution milestone rather than a secured business combination. The absence of substantive commercial claims means market positioning, revenue projections, partnership negotiations, or litigation risks remain unverified until a subsequent Definitive Proxy or Prospectus Supplement is filed, leaving redemption calculus and extension viability entirely dependent on subsequent filings and Nasdaq compliance maintenance.

This filing advances the S-1 qualification process for Drugs Made In America Acquisition II Corp., confirming that the company remains in a pre-business combination stage with no disclosed adjustments to redemption deadlines, trust accounting, or business combination timelines. Regarding sponsor conduct and deal mechanics, the explicit mapping of transferee status to existing lock-up covenants clarifies how founder equity will circulate post-merger and defines shareholder rights during the qualification window. The specific attention to Rule 14e-5 compliance for secondary purchases from public shareholders indicates the Company and SEC Staff are structuring potential tender-like interactions to align with federal market safeguards. No extension requests or changes to shareholder voting windows were reported. Lynn Stockwell is identified solely as Chief Executive Officer in the distribution list. All operational and structural assertions derive directly from the Company’s disclosure revisions, SEC Staff commentary, and counsel’s submission.

The filing sets forth the final terms of the $500 million SPAC IPO ($10.00 per unit), including trust mechanics, 24-month completion window, redemption rights (with a 15% cap if shareholder vote is used), and lock-up provisions. It also discloses material conflicts of interest (all officers/directors also serve DMAA, a sister SPAC), the sponsor's nominal cost basis ($0.0024 per founder share), and the ongoing BGXX bankruptcy and litigation involving CEO Lynn Stockwell and her spouse, which may affect management credibility and deal execution risk.

Scrutiny over founder share attribution, lock-up applicability, and secondary trading rules directly impacts sponsor conduct, control mechanics, and pre-combination equity liquidity. Unclear transfer restrictions or noncompliant secondary purchases could disrupt redemption expectations, complicate deal timing, and delay S-1 effectiveness. The Division’s request to update exhibits and clarify signatory status highlights enforcement focus on governance structures that investors track when evaluating trust preservation, extension viability, and sponsor alignment. The document contains no independent claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel beyond the addressee identification.

For investors tracking this pre-IPO SPAC: (1) Trust value is set at $10.00 per unit; (2) The SPAC has 24 months from closing to complete a deal; (3) Sponsor paid $35,000 for 14.375 million founder shares ($0.0024/share), creating massive potential dilution for public shareholders; (4) A material risk is disclosed: the CEO (Lynn Stockwell) and her spouse (John Stockwell, special advisor) are involved in a Chapter 11 proceeding and litigation at Bright Green Corp., and all officers/directors also serve DMAA, a competing SPAC with a pre-existing fiduciary obligation to receive deal opportunities before this SPAC. The filing signals current operations and conflicts but no new corporate action.

This is the foundational IPO registration for a $500 million SPAC targeting pharmaceutical acquisitions. Key mechanics for investors: the trust holds $10.00 per public share; shareholders have redemption rights upon business combination; the company has 24 months from closing to complete a deal; the sponsor's founder shares ($0.003 per share) create massive dilution and a conflict of interest; sponsor and officers are locked up for 6 months post-deal or until a $12.50 share price trigger; the sponsor's sole member Lynn Stockwell is also CEO of a parallel SPAC (DMAA) and involved in a Chapter 11 proceeding at Bright Green, raising sponsor conduct concerns. The filing provides the complete terms of the offering, including unit structure (one share plus one-tenth share right), underwriting discounts, deferred compensation, and the limitation on redemptions exceeding 15% of public shares if a shareholder vote is held.

Establishes all key mechanics for the SPAC: $10.00-per-share trust, 24-month completion deadline, redemption rights (with 15% cap if shareholder vote is used), no maximum redemption threshold, sponsor founder shares purchased for ~$0.0024 per share, private placement of 1,200,000 units to sponsor and Cantor, lock-up provisions, and disclosure of material conflicts including the overlapping management with DMAA (another SPAC still searching) and the Bright Green Corp. Chapter 11 and related litigation involving Lynn Stockwell and John Stockwell.

Investors tracking redemption deadlines, trust value preservation, and extension mechanics should note that the amended filings do not reset trust payouts or statutory voting thresholds, but they materially reshape how cash-out decisions are priced against execution risk. The documented 4.6% quorum observation lowers the effective barrier to approving an extension or merger, altering the strategic calculus for holders weighing immediate liquidity versus continued speculative exposure. The explicitly stated $0.0014/share sponsor entry point versus public valuation creates a stark incentive divergence that typically pressures deal terms near expiration. Governance simplification via classified board removal reduces pre-combination friction. Until the full amended registration statement is published, investors cannot yet calculate exact extension fee tiers or compare precise redemption rates from the cited prior transaction, making this disclosure cycle the primary vector for adjusting position sizing ahead of the next SEC comment or business combination announcement.

Establishes the SPAC's terms: $900 million trust ($10.00 per share), 24-month completion window, redemption rights, sponsor's nominal founder shares, conflicts with another SPAC (DMAA), and a going concern qualification. Provides investors with mechanics for redemptions, extensions, and sponsor conduct.

This regulatory review governs the timeline to prospectus effectiveness and directly alters shareholder redemption calculus. Explicit extension caps and sponsor fallout clauses will determine whether existing trust balances remain invested or trigger accelerated liquidation schedules. The SEC’s insistence on resolving the 4.6% versus zero-share voting threshold contradiction reduces procedural litigation risk that historically precipitates mass redemptions during special meetings. Scrutiny of the $35,000 founding cost, worthless-downside structures, and previous redemption outcomes exposes principal-agent tensions that typically drive pre-combination cash exits. Mandating disclosure of secondary issuance dilution, bridge capital sourcing, and classified board entrenchment forces investors to price governance and capital stack alterations accurately. Until the revised S-1 incorporates these comments, market participants cannot independently verify extension feasibility, model precise trust distribution scenarios, or benchmark sponsor alignment against disclosed historical exit patterns.

Provides complete terms: $900 million trust ($10.00 per public share), 24-month deadline to complete a business combination, unit structure (one ordinary share + one right), sponsor economics, redemption mechanics, and conflicts of interest. Investors can evaluate the SPAC's structure and risks.

What changed: Form 12b-25 Notification of Late Filing (routine compliance exhibit) requesting relief under Securities and Exchange Commission Rule 12b-25 to postpone submission of the Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Chief Executive Officer Roger E. Bendelac signed the notification on April 1, 2026, stating the registrant could not timely compile all financial statement information and related disclosures without unreasonable effort or expense. The company now expects to file the Annual Report on or before April 15, 2026. Bendelac certifies that all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months have been filed, and the registrant does not anticipate reflecting any significant change in results of operations in the subject report. The SPAC retains SEARCHING status, and the reported trust per share remains $10.28. No charter amendment, explicit redemption deadline modification, or shareholder extension vote is recorded in this filing. Why it matters: For investors monitoring redemption calendars, extension triggers, and sponsor execution, a late-form filing halts the disclosure pipeline required to evaluate a proposed business combination or vote on a trust extension. Because Bendelac attributes the delay to compiling financial data rather than market dynamics or target scarcity, sponsors face scrutiny over auditor readiness, internal controls, and whether acquisition due diligence can advance while baseline financials remain unresolved. The document contains no claims regarding customers, revenue, market size, commercial strategy, technology development, partnership agreements, active litigation, or personnel changes; it consists exclusively of procedural certification and timeline recalibration. Without the audited 10-K, shareholders cannot verify trust allocation, assess whether remaining liquidity covers potential extension fees or liquidation costs, or time redemptions against audited NAV adjustments. This procedural hold materially extends the window during which liquidation risk accumulates and decision-making on capital deployment remains paused until sponsor disclosures resume.

What changed: A Form 8-K current report accompanied by Exhibits 10.1 (Letter of Intent), 10.2 (Addendum to Letter of Intent), and 10.3 (Bridge Financing Convertible Promissory Note) detailing SPAC bridge capital arrangements. This document is a routine compliance exhibit (Form 8-K) reporting the entry into agreements for bridge financing. Regarding redemption deadlines, trust value, extensions, deal progress, and sponsor conduct: the filing contains no information on shareholder redemption rights, trust account balances, extension amendments, identified merger targets, or modifications to existing deadlines. The Company stated it intends to use the bridge loan proceeds for 'accounting expenses, audit expenses and other expenses related to the Business Combination' and regulatory costs to maintain its NASDAQ listing, which supports ongoing operations but does not accelerate or alter any de-SPAC timeline. Chief Executive Officer Roger Bendelac signed the Letter of Intent, the Addendum, and the Bridge Note, demonstrating active capital raising efforts. The Addendum explicitly clarifies that S.E.E Capital Partners Ltd. 'acts solely as advisor' and 'shall not be deemed the sponsor or issuer.' Regarding other substance: The original Letter of Intent (dated March 5, 2026) outlined a proposed Senior Convertible Note investment of USD $1,500,000. The Addendum (dated March 9, 2026) modified the aggregate financing to $1,400,000, with the parties acknowledging the $100,000 difference represents 'due diligence and negotiation costs associated with the Investor’s advisor,' which the Investor alone agreed to settle with the Transaction Advisor. The document records an initial bridge note of $150,000 issued on March 11, 2026, functioning as a deposit toward the $1,400,000 total. The remaining $1,250,000 is contingent on a definitive Convertible Note Purchase Agreement. A minimum funding milestone requires that 'at least $400,000 in aggregate funding shall be disbursed to the Company on or prior to March 30, 2026.' Upon consummation of a business combination, the Investor may convert the outstanding principal at a 35% discount to the combined entity's market price. Disbursements will require joint authorization from an IOLA escrow account. The note bears no interest, matures nine months from issuance unless converted or credited, and is governed by Cayman Islands law. No claims regarding customers, revenue, market size, technology, strategic partnerships, litigation, or personnel changes appear in the text. Why it matters: Although the filing does not update the redemption calendar, trust mechanics, or de-SPAC schedule, it materially affects near-term liquidity and listing survival. The mandatory $400,000 disbursement by March 30, 2026 establishes a concrete cash-inflow checkpoint. The 35% conversion discount and sole-discretion conversion rights favor the lender upon a future combination, potentially diluting existing shareholders at the time of the event. Tracking whether the $1,250,000 remainder closes and how the escrow release mechanism operates will indicate whether management is preserving runway for active target evaluation or merely covering administrative overhead ahead of potential deadlines.

What changed: A Form 8-K current report detailing the departure of senior officers, the appointment of a replacement Chief Executive Officer, and disclosures regarding related-party working capital transactions. The filing reports that the Sponsor withdrew an aggregate $1,100,000 from the Company's working capital account between the September 26, 2025 initial public offering and September 30, 2025. Document breakdowns indicate $325,000 repaid an outstanding working capital note to the Sponsor, $208,000 repaid offering costs and expenses to the Sponsor, and a $566,269 overpayment to the Sponsor. Additionally, between September 30, 2025 and December 31, 2025, the Sponsor withdrew no less than $200,000 to pay for expenses unrelated to the Company. The Board directed repayment of this 'Overpayment Amount,' but the Board and Chief Financial Officer learned on February 12, 2026 that the Sponsor could not return it. Consequently, on February 28, 2026, the Board removed Lynn Stockwell as Chief Executive Officer, Executive Chair of the Board, and a Board member. Roger Bendelac was appointed Chief Executive Officer effective the same date, with compensation undetermined. Why it matters: The Sponsor's diversion of working capital for non-company purposes and subsequent failure to repay directly threatens the liquidity pool backing the trust account, posing a material risk to shareholder redemption values and potentially complicating the remaining search timeline. The abrupt leadership change during the SEARCHING phase introduces governance turbulence and execution uncertainty. While the filing does not adjust official redemption deadlines or recalculate per-share trust value, the unresolved status of the unrecovered funds highlights sponsor conduct that could delay or derail a future business combination. The appointment of Roger Bendelac—a 69-year-old consultant with over 30 years of investment banking and advisory experience—signals an attempted operational reset, though his specific compensation arrangements remain pending Board approval.

What changed: Form 8-K Current Report filed under Item 8.01 (Other Events) by Drugs Made In America Acquisition II Corp. The Company reports that, per its own disclosure, the sponsor made improper withdrawals from the working capital account between September 26, 2025, and December 31, 2025. The board of directors immediately took action to confirm these irregularities did not reach the trust account. Chief Executive Officer Roger Bendelac executed the filing, which states the trust account holds approximately $507,841,957 as of March 6, 2026. The report outlines no alterations to redemption windows, extension provisions, or business combination milestones. Why it matters: Sponsor-initiated working capital impropriety introduces governance and proxy-voting risk, signaling potential internal control deficiencies prior to a merger. However, because the board independently verified the diversion was confined to working capital, the full $507,841,957 trust pool remains available for shareholder redemptions, leaving the redemption floor unchanged from the filing's perspective. Reduced working capital may force reliance on external funding or trigger extension negotiations if operating expenses outpace remaining liquidity before a deal closes. The document provides no information on target prospects, customer relationships, revenue streams, market positioning, or technological assets beyond the fund irregularity and its verification.

What changed: SEC Form 8-K - Current report disclosing executive departures and appointments under Item 5.02. On October 8, 2025, Glenn Worman delivered a resignation notice effective that day from his positions as Chief Financial Officer and principal financial and accounting officer. Mr. Worman indicated the resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices. On November 17, 2025, the Company appointed Saleem Elmasri as the new Chief Financial Officer and principal financial and accounting officer, executing a Master Services Agreement (Consulting Agreement) with Titan Advisory Services LLC to provide these services. Why it matters: The filing transitions financial oversight to an outsourced specialist during the SPAC's 'SEARCHING' phase, prior to any business combination. Under the Consulting Agreement, the Company pays Titan Advisory Services LLC $3,500 per month, or $42,000 per year. Furthermore, Chief Executive Officer Lynn Stockwell shall transfer 100,000 shares of the Company’s ordinary shares to Mr. Elmasri upon engagement. The new CFO’s profile lists him as a CPA with 20 years of experience in financial and management consulting, beginning at PricewaterhouseCoopers and currently serving as Managing Partner at Titan Advisory Services LLC. Regarding SPAC mechanics, this personnel shift carries no implications for the redemption calendar, triggers no extension votes, leaves the trust value unchanged, and reveals no new deal progress, customer claims, revenue metrics, or litigation. Sponsor conduct remains unremarked upon beyond the standard equity compensation and indemnity expectations outlined for officers.

What changed: Form 10-Q (Quarterly Report) for Drugs Made In America Acquisition II Corp. for the quarter ended September 30, 2025, the first quarterly report following its initial public offering. The company completed its IPO of 50,000,000 units at $10.00 per unit on September 26, 2025, generating $500,000,000 in gross proceeds, which were placed in a trust account. Simultaneously, it sold 1,200,000 Private Placement Units to the sponsor and Cantor for $12,000,000. The trust account held $500,109,355 as of September 30, 2025, representing $10.00 per public share redemption value. The company has 24 months from the IPO closing to complete a business combination. Prior to the IPO, the sponsor surrendered 30,347,722 founder shares in February and May 2025, reducing its stake to 14,375,000 founder shares. The company reported a net loss of $143,558 for the nine months ended September 30, 2025, and has working capital of $219,011. Management identified material weaknesses in internal control over financial reporting due to limited personnel. Why it matters: This filing establishes the baseline trust value ($10.00 per share), the 24-month deadline (September 2027), and the sponsor's reduced ownership. It confirms no deal target has been selected and that the company is searching for a target in the pharmaceutical industry. The going concern disclosure and material weakness in internal controls are notable risk factors. The over-allotment option remains available, which could affect share count. The filing also details related party transactions, including the administrative services agreement and founder share lock-up provisions.

What changed: This document IS a Form 12b-25 (Notification of Late Filing), which is a routine compliance exhibit filed with the Securities and Exchange Commission. Regarding mechanics bearing on redemption deadlines, trust value, extensions, deal progress, or sponsor conduct: the filing contains zero provisions affecting the SPAC’s business combination timeline, redemption procedures, trust account calculations, or merger status. It does not request an extension of the combination deadline. Regarding other substance: Chief Executive Officer Lynn Stockwell states that the quarterly financial statements 'could not be completed in sufficient time to solicit and obtain the necessary review of the subject report and signatures thereto in a timely fashion.' She also certifies that all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months have been filed, and represents that the company anticipates 'no significant change in results of operations from the corresponding period for the last fiscal year.' The filing provides no data on customers, revenue, market size, strategy, technology, partnerships, or litigation. It was signed on November 14, 2025. Securities and Exchange Commission registrant Drugs Made In America Acquisition II Corp. has formally notified the Commission that its Quarterly Report on Form 10-Q for the period ended September 30, 2025, will miss the statutory deadline. Under Rule 12b-25(b), the registrant binds itself to file the complete report on or before the fifth calendar day following the original due date. Why it matters: Investors tracking redemption windows and governance transparency should log this procedural deferral. The delayed quarterly disclosure postpones public visibility into current cash balances, related-party loan activity, sponsor advancement schedules, and any unpublicized target outreach. The filing introduces no changes to per-share trust valuations, redemption mechanics, or merger contingency clocks.

What changed: This document is a U.S. Securities and Exchange Commission Form 4 insider ownership report submitted by Director Catherine Do for Drugs Made In America Acquisition II Corp. According to the filing, on September 26, 2025, Director Do acquired 100,000 shares via a transaction coded as 'other,' leaving her with exactly 100,000 shares afterward. The report does not state the purchase price, share class, funding source, or whether the blocks were traded on an exchange or privately negotiated. It contains no disclosures relating to the company’s trust account, the reported $10.28 per-share trust reserve, upcoming redemption deadlines, extension procedures, target acquisition progress, or sponsor conduct. Why it matters: Because the Form 4 attributes no strategic rationale or financing terms to the director’s purchase, the update reflects a routine change in individual holdings rather than a mechanical alteration to the SPAC’s capital structure. The transaction does not shift the $10.28 per-share trust value, extend any redemption window, influence business combination timelines, or modify sponsor voting power or lock-up obligations. Investors tracking trust liquidity, shareholder vote mechanics, or promoter alignment should note that unpriced, unlabeled insider acquisitions during the SEARCHING phase do not override prospectus-defined redemption protocols or guarantee impending deal execution.

What changed: Form 8-K Current Report disclosing the consummation of the initial public offering and private placement, accompanied by a balance sheet and notes to financial statements. Per Item 8.01 and the attached financial notes, the company reported the consummation of its IPO of 50,000,000 units at $10.00 per unit, generating aggregate gross proceeds of $500,000,000. Simultaneously, it closed a private placement of 1,200,000 units at $10.00 per unit, yielding $12,000,000 in proceeds purchased by Drugs Made In America Acquisition II LLC (700,000 units) and Cantor Fitzgerald & Co. (500,000 units). As of September 26, 2025, $500,000,000 was deposited into the trust account. The filing establishes a 24-month Combination Period to complete a business combination, discloses total transaction costs of $28,357,609 (broken down by management into $10,000,000 in cash underwriting fees, $17,500,000 in deferred underwriting fees, and $857,609 in other offering costs), and confirms the sponsor holds 14,375,000 founder shares, with up to 1,875,000 subject to forfeiture if the underwriters' 7,500,000-unit over-allotment option is not fully exercised. Note 10 attributes the subsequent repayment of the $325,000 promissory note and $208,731 due to the sponsor on September 29, 2025, to the company. Why it matters: This filing finalizes the SPAC's funding mechanics and definitive calendar for public shareholders, confirming that $500,000,000 is held in the trust account to back redemption obligations. Management stated the company intends to focus on the pharmaceutical industry but explicitly disclosed that no target has been selected and no substantive discussions have been initiated. Underwriters agreed to waive their right to the $17,500,000 deferred underwriting commissions if a business combination is not completed within the Combination Period, protecting trust value for redeeming investors. Independent auditor MaloneBailey, LLP raised a going concern matter, noting the company has incurred significant costs without generating operating revenues and faces mandatory liquidation if a deal is not consummated, which fundamentally alters the risk assessment for holders of the ordinary shares and rights listed on Nasdaq.

What changed: A routine compliance exhibit—specifically a Joint Filing Agreement (Exhibit 99.1) attached to a Schedule 13D, executed on October 1, 2025, by and between Drugs Made In America Acquisition II LLC and Lynn Stockwell. The filing alters nothing regarding redemption deadlines, trust value, extension mechanics, or deal progress. As authored by the signatories, it merely establishes procedural coordination permitting two reporting persons to submit a single Schedule 13D on their combined beneficial ownership of DMII ordinary shares under Rule 13d-1(k)(1). Each signatory accepts sole responsibility for the completeness and accuracy of information pertaining to themselves, disclaiming liability for the other's data unless they possess knowledge of its inaccuracy. Why it matters: The agreement discloses no customers, revenue projections, market size estimates, technology roadmaps, partnership terms, litigation posture, or executive shifts. Its only substantive signal is that Lynn Stockwell and the sponsor LLC are consolidating their 13D reporting obligations, indicating aggregated holdings that cross the statutory disclosure threshold. Without the primary Schedule 13D body—which would typically list aggregate shares owned, acquisition dates, price paid, and purpose of the transaction—investors cannot determine whether this reflects passive accumulation, a targeted warrant/cash position, or early merger-stage coordination. The filing does not shift the tracked $10.28 trust per share, initiate any extension vote, or alter the SEARCHING status. Materiality is assessed as low pending receipt of the parent filing's ownership tables.